The expanded Farxiga and Xigduo XR labels have been approved to treat patients with T2D and moderate renal impairment, which is a chronic kidney disease with an estimated The post AstraZeneca gets FDA expanded approval for Farxiga and Xigduo XR appeared first on Pharmaceutical Business review.
Thu Feb 28, 2019 12:07
Clinical Trials, Ahead of Print.
Thu Feb 28, 2019 10:38
New investor Seventure Partners, via its microbiome-focused fund Health for Life Capital™, led the financing along with existing investors Longwood Fund, Domain Associates, Heritage Medical Systems and a The post Axial Biotherapeutics raises $25m in Series B financing appeared first on Pharmaceutical Business review.
Thu Feb 28, 2019 14:10
PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that they are looking forward to revealing 17 presentations that detail their research into neuroendocrine tumors (NETs) at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference, which is taking place in Barcelona, Spain between 6th-8th March 2019. One of the key presentations, titled (Abstract #H14) ‘Development of a new and improved delivery system for lanreotide autogel/depot to furt
Thu Feb 28, 2019 08:30
PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext : IPN ; ADR : IPSEY) a annoncé aujourd'hui la présentation de 17 abstracts portant sur les recherches relatives aux tumeurs neuroendocrines (TNE) dans le cadre de la 16e édition de la Conférence annuelle de l’European Neuroendocrine Tumor Society (ENETS), qui se tiendra à Barcelone, en Espagne, du 6 au 8 mars 2019. L'une des présentations clés (Abstract H14), intitulée « Development of a new and improved delivery system for lanreotide aut
Thu Feb 28, 2019 08:30
ZURICH--(BUSINESS WIRE)--VIFOR PHARMA GROUP SUPPORTS RARE DISEASE DAY 2019
Thu Feb 28, 2019 08:00
COPENHAGUE, Danemark--(BUSINESS WIRE)--Les sociétés pharmaceutiques Janssen de Johnson & Johnson ont annoncé aujourd'hui que 18 abstracts sponsorisés par les sociétés seront présentées lors du 14e congrès de l'Organisation européenne de la maladie de Crohn et de la RCH (ECCO), qui se tiendra à Copenhague, au Danemark, du 6 au 9 mars prochains. Sponsorisées par la société, les six principales présentations (orales et orales numériques) comprendront de nouvelles données de l'étude UNIFI de Ph
Thu Feb 28, 2019 04:15
COPENHAGEN, Danimarca--(BUSINESS WIRE)--Le Società farmaceutiche Janssen di Johnson & Johnson hanno annunciato oggi la presentazione di 18 abstract sponsorizzati dalla società al 14o Congresso della European Crohn’s and Colitis Organisation (ECCO), l'associazione europea per la colite e il morbo di Crohn, che si svolge a Copenhagen, Danimarca, al 6 al 9 marzo. Gli eventi principali comprendono sei presentazioni orali o digitali e orali sponsorizzate dall'azienda, compresi nuovi dati dallo s
Thu Feb 28, 2019 01:50
DUBLIN--(BUSINESS WIRE)--The "Capsule Endoscopes - Medical Devices Pipeline Assessment, 2019" report has been added to ResearchAndMarkets.com's offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start a
Thu Feb 28, 2019 00:07
SAN DIEGO--(BUSINESS WIRE)--Turning Point Therapeutics, Inc., a clinical-stage precision oncology company developing novel drugs that address treatment resistance, will present preclinical data next month highlighting the potent activity of its kinase inhibitors against targeted oncogene drivers and their mutations. Four studies were accepted for presentation during poster sessions at the American Association for Cancer Research (AACR) Annual Meeting taking place March 29 to April 3 in Atlanta,
Wed Feb 27, 2019 23:47
WARREN, N.J.--(BUSINESS WIRE)--Celularity, Inc., a clinical-stage cell therapeutics company developing allogeneic cellular therapies harnessed from human placentas, today announced it will present first-ever clinical and pre-clinical results from its comprehensive placental hematopoietic stem cell derived natural killer (PNK) cells oncology program at the 2019 American Association for Cancer Research (AACR) Annual Meeting being held from March 29 – April 3, 2019 in Atlanta, Georgia. Investigati
Wed Feb 27, 2019 23:45
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that 11 posters highlighting continued innovation in the field of ADCs will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting to be held March 29 – April 3, 2019 in Atlanta, Georgia. “ImmunoGen remains at the forefront of ADC innovation and the data to be presented at AACR furthe
Wed Feb 27, 2019 23:31
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor currently in a Phase 1 clinical trial focused on ovarian and breast cancers, and on SY-5609, its selective oral CDK7 inhibitor that the company has named as its next development candidate, at the American
Wed Feb 27, 2019 23:31
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its fourth quarter and fiscal year 2018 financial results on Wednesday, March 6, 2018, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants and (216) 562-0466 for international participants, with participant code 5072004. A webcast replay will be available via the “Investors” tab on the GlycoMimetics webs
Wed Feb 27, 2019 23:30
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2018. “A series of significant achievements in 2018 have positioned Acceleron to execute on a number of key milestones across the entire pipeline during 2019 and 2
Wed Feb 27, 2019 23:05
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 500,000 shares at the public offering price of $150.00 per share, less the underwriting discount. The
Wed Feb 27, 2019 23:01
A series of clinical trials have concluded that a new therapy, alongside a novel method of delivery, could be effective in treating Parkinson's disease.
Wed Feb 27, 2019 17:00
OAKLAND, Calif.--(BUSINESS WIRE)--Hound Labs, Inc., a leader in the field of breath diagnostics, today announced results of its second clinical trial with the University of California, San Francisco (UCSF), in which researchers measured THC1 in breath. Results from this landmark study confirm – for the first time in a clinical trial – THC is present in breath for two to three hours after smoking, which is the same duration as peak impairment according to government studies2. The trial also conc
Wed Feb 27, 2019 18:00
COPENHAGEN, Denmark--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson today announced 18 company-sponsored abstracts will be presented at the 14th Congress of the European Crohn’s and Colitis Organisation (ECCO) taking place in Copenhagen, Denmark from 6-9 March. Highlights include six company-sponsored oral or digital oral presentations, including new data from the Phase 3 UNIFI study evaluating the efficacy and safety of STELARA® (ustekinumab) maintenance therapy
Wed Feb 27, 2019 17:51
NEW ALBANY, Ohio--(BUSINESS WIRE)--Myonexus Therapeutics Announces Accelerated Acquisition by Sarepta Therapeutics Following Positive Preliminary Data from LGMD2E Program
Wed Feb 27, 2019 16:14
HIGH POINT, N.C.--(BUSINESS WIRE)--vTv Therapeutics Announces 2018 Fourth Quarter and Full Year Financial Results and Update
Wed Feb 27, 2019 15:30
DUBLIN--(BUSINESS WIRE)--The "Anal Cancer Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides top line data relating to the clinical trials on Anal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
Wed Feb 27, 2019 15:04
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved a label update for FARXIGA® (dapagliflozin) and XIGDUO® XR (dapagliflozin and metformin HCl extended-release) expanding use in patients with type 2 diabetes (T2D) and moderate renal impairment (chronic kidney disease with an estimated glomerular filtration rate [eGFR] of 45-59 mL/min/1.73 m2). FARXIGA is indicated as an adjunct to diet and exercise to improve glycemic contr
Wed Feb 27, 2019 15:00
DURHAM, N.C.--(BUSINESS WIRE)--Mycovia announces the initiation of a Phase 3 clinical study to evaluate the safety and efficacy of VT-1161 and its ability to treat acute infections in women with RVVC.
Wed Feb 27, 2019 15:00
DUBLIN--(BUSINESS WIRE)--The "Altitude Sickness (Acute Mountain Sickness) Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides top line data relating to the clinical trials on Altitude Sickness (Acute Mountain Sickness). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 &
Wed Feb 27, 2019 14:54
DUBLIN--(BUSINESS WIRE)--The "Anaplastic Large Cell Lymphoma (ALCL) Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering. "Anaplastic Large Cell Lymphoma (ALCL) Global Clinical Trials Review, H2, 2018" provides an overview of Anaplastic Large Cell Lymphoma (ALCL) clinical trials scenario. This report provides top line data relating to the clinical trials on Anaplastic Large Cell Lymphoma (ALCL). Report includes an overview of trial numbers
Wed Feb 27, 2019 14:38
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the Company’s VP of Business Development, Sari Fishman will participate in the Bio Asia International Conference in Tokyo, Japan on March 5th and 6th, 2019. The BIO Asia International Conference brings together the global biotechnology and pharmaceut
Wed Feb 27, 2019 14:00
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will participate in two upcoming investor conferences in March. Cowen and Company 39th Annual Health Care ConferenceDate: Tuesday, March 12, 2019Time: 9:20 a.m. Eastern TimeLocation: Boston, MA Oppenheimer 29th Annual Healthcare Conference – Analyst-Led
Wed Feb 27, 2019 14:00
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Closes At-The-Market Facility
Wed Feb 27, 2019 13:30
DUBLIN--(BUSINESS WIRE)--The "Anaplastic Oligoastrocytoma Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering. "Global Anaplastic Oligoastrocytoma Clinical Trials Review, H2, 2018" provides an overview of Anaplastic Oligoastrocytoma clinical trials scenario. This report provides top line data relating to the clinical trials on Anaplastic Oligoastrocytoma. Report includes an overview of trial numbers and their average enrollment in top cou
Wed Feb 27, 2019 13:08
IRVINE, Kalifornien--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), ein Medizintechnikunternehmen, das sich auf die Entwicklung und Vermarktung neuartiger, implantierbarer Geräte zur sakralen Neuromodulation (SNM) spezialisiert hat, die zur Behandlung von Fehlfunktionen des Harn- und Darmtraktes verwendet werden, hat heute die Einreichung entscheidender klinischer Daten aus der ARTISAN-SNM-Schlüsselstudie bekanntgegeben, die für den Erhalt der Marktzulassung für das Axon
Wed Feb 27, 2019 13:06
Based in Cambridge of Massachusetts, Anthos Therapeutics will develop and commercialize genetically and pharmacologically validated therapies for high-risk cardiovascular patient populations. Anthos chairman and Blackstone Life Sciences head The post Anthos Therapeutics launched to advance targeted therapies for cardiovascular disease appeared first on Pharmaceutical Business review.
Wed Feb 27, 2019 11:40
“As we continue to transform Bausch Health, we are now pivoting to offense with research investments and strategic acquisitions that augment our core businesses. We are excited to The post Bausch Health to buy certain assets of Synergy Pharmaceuticals appeared first on Pharmaceutical Business review.
Wed Feb 27, 2019 11:40
OXFORD, England--(BUSINESS WIRE)--Emergex today announces the appointment of Athanasios Papadopoulos, MD, as Chief Medical Officer (CMO), effective 1st March 2019.
Wed Feb 27, 2019 11:00
Imbrium will leverage TetraGenetics’ proprietary TetraExpress system to advance monoclonal antibodies that target specific ion channels that are scientifically important in the modulation of pain sensation. The goal The post Imbrium, TetraGenetics announce research collaboration and license option to develop biologic therapeutics for pain appeared first on Pharmaceutical Business review.
Wed Feb 27, 2019 09:39
IRVINE, Californie--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ : AXNX), une société de technologie médicale spécialisée dans le développement et la commercialisation de nouveaux dispositifs implantables de neuromodulation sacrée (« NMS ») pour le traitement des problèmes de dysfonctionnement urinaire et intestinal, a annoncé aujourd’hui le dépôt des données cliniques pivot de l’étude clinique pivot ARTISAN-SNM, visant à obtenir l’autorisation de commercialisation de la Food
Wed Feb 27, 2019 06:00
California Clinical Trials Medical Group managed by PAREXEL, located in Glendale, CA is currently seeking healthy volunteers to participate in a clinical trial that requires taking an investigational drug or placebo.If you qualify, the study may involve:A screening visit1 admission of 3 days/2 nights2 follow-up visits1 Phone call follow-up
Mon Feb 25, 2019 00:00
IRVINE, California--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), una compañía de tecnología médica centrada en el desarrollo y comercialización de novedosos dispositivos implantables de neuromodulación sacral ("SNM") para el tratamiento de la disfunción urinaria e intestinal, ha anunciado hoy la presentación de datos clínicos decisivos del estudio clínico pivotal ARTISAN-SNM diseñado para obtener la aprobación de comercialización de la Administración de Alimentos y Med
Tue Feb 26, 2019 20:12
IRVINE, Californië--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) een medisch technologiebedrijf dat zich concentreert zich op de ontwikkeling en commercialisering van nieuwe implanteerbare Sacrale Neuromodulatie (“SNM”) apparaten voor de behandeling van urine- en darmstoornissen, kondigde vandaag de indiening aan van cruciale klinische gegevens van de ARTISAN-SNM cruciale klinische studie die is ontworpen om de goedkeuring van de Amerikaanse Food & Drug Administrati
Tue Feb 26, 2019 20:12
ATLANTA et ZURICH--(BUSINESS WIRE)--Lori Chmura, PDG de Dune Medical Devices, société qui fabrique le dispositif à succès, MarginProbe, devrait livrer une présentation à l’occasion du 1er Congrès Sachs des sciences de la vie « Go For Israel », le mardi 26 février à 15 h 15 HE, au Hilton Zurich Airport, à Zurich, en Suisse. Dune Medical Devices est une société au stade commercial qui révolutionne la technologie de caractérisation des tissus dans le cadre de la chirurgie, du diagnostic et du trai
Tue Feb 26, 2019 20:02
ATLANTA und ZÜRICH--(BUSINESS WIRE)--Lori Chmura, CEO von Dune Medical Devices, Hersteller des erfolgreichen MarginProbe-Geräts, wird am Dienstag, den 26. Februar um 15:15 Uhr MEZ auf der ersten Life-Sciences-Konferenz „Go For Israel“ von Sachs eine Präsentation im Hilton Zürich Airport, Zürich, Schweiz, halten. Dune Medical Devices ist ein kommerziell arbeitendes Unternehmen, das die Technologie der Gewebecharakterisierung in der chirurgischen Behandlung, Diagnose und zielgerichteten Therapie
Tue Feb 26, 2019 20:02
瑞士纳沙泰尔--(BUSINESS WIRE)--(美国商业资讯) -- Masimo (NASDAQ: MASI)今天发布了4个临床病例系列的研究结果，该结果近期发表于《加拿大麻醉科杂志》(Canadian Journal of Anesthesiology)，蒙特利尔大学的研究人员发现，联合运用Masimo SedLine®脑功能监护仪与O3®局部氧饱和度仪有助于了解和处治心脏手术期间的脑去氧饱和。 Etienne Couture、Alain Deschamps和André Denault等三位博士推测，在既往制订的基于Masimo O3近红外光谱仪(NIRS)的临床处治规程上，添加采用Masimo SedLine处理后EEG参数（即患者状态指数(Patient State Index, PSi)）的处理后脑电图(pEEG)，有望帮助指引脑去氧饱和发作的处治。他们在该病例研究系列中，描述了4例患者接受心脏手术期间各种临床处治方式相结合的影响。随后，研究人员勾画了一系列场景，这些场景依据NIRS和pEEG变化、以及SedLine提供的相关监护数据（例如密度谱阵列(DSA)和谱边缘频
Tue Feb 26, 2019 19:06
瑞士納沙泰爾--(BUSINESS WIRE)--(美國商業資訊) -- Masimo (NASDAQ: MASI)今天發布了4個臨床病例系列的研究結果，該結果近期發表於《加拿大麻醉科雜誌》(Canadian Journal of Anesthesiology)，蒙特婁大學的研究人員發現，聯合運用Masimo SedLine®腦功能監護儀與O3®局部血氧飽和度儀有助於瞭解和處治心臟手術期間的腦去氧飽和。 Etienne Couture、Alain Deschamps和André Denault等三位博士推測，在既往制訂的以Masimo O3近紅外光譜儀(NIRS)為基礎的臨床處治規程上，添加採用Masimo SedLine處理後EEG參數（即患者狀態指數(Patient State Index, PSi)）的處理後腦電圖(pEEG)，可望幫助指引腦去氧飽和發作的處治。他們在該病例研究系列中，描述了4例患者接受心臟手術期間各種臨床處治方式相結合的影響。隨後，研究人員勾畫了一系列場景，這些場景依據NIRS和pEEG變化、以及SedLine提供的相關監護資料（例如密度譜陣列(DSA)和頻譜
Tue Feb 26, 2019 19:06
SAN ANTONIO--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/Cancer?src=hash" target="_blank"gt;#Cancerlt;/agt;--Rapamycin Holdings has launched a new corporate brand - Emtora Biosciences - and hired Dr. Carole Spangler Vaughn as CEO.
Tue Feb 26, 2019 18:00
IRVINE, California--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), una società operante nel settore delle tecnologie mediche impegnata nello sviluppo e nella commercializzazione di innovativi dispositivi impiantabili per la neuromodulazione sacrale (NMS) per il trattamento delle disfunzioni della vescica e dell’intestino, ha comunicato oggi di aver depositato i dati clinici principali derivati dallo studio clinico principale ARTISAN-SNM ai fini dell’ottenimento dell’auto
Tue Feb 26, 2019 16:34
SAN FRANCISCO--(BUSINESS WIRE)--Published in BMJOpen, Virta trial demonstrates that type 2 diabetes reversal results exceed AASLD treatment guidelines for NAFLD at 1 year.
Tue Feb 26, 2019 16:00
DENVER--(BUSINESS WIRE)--Nexien BioPharma, Inc. (“Nexien” or the “Company”) (OTCQB: NXEN), a next generation biopharmaceutical company focused on research, development and commercialization of novel FDA-compliant cannabinoid pharmaceuticals and related drug delivery systems, today announced encouraging results of clinical observations of patient groups consisting of patients suffering from non-dystrophic myotonia and myotonic dystrophies (DM) type 1 and 2, indicating that specific cannabinoid f
Tue Feb 26, 2019 16:00
PRINCETON, N.J.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/dryeye?src=hash" target="_blank"gt;#dryeyelt;/agt;--Oyster Point Pharma raises $93M Series B financing to support the Phase 3 development of the company's investigational treatment for Dry Eye Disease.
Tue Feb 26, 2019 16:00
SAN DIEGO--(BUSINESS WIRE)--Eight leading health care and research organizations in the U.S. and Canada have signed an agreement to launch the Medical Genome Initiative, a consortium that will work to expand access to high-quality clinical whole genome sequencing (cWGS) for the diagnosis of genetic diseases. The Initiative will focus on the publication of common laboratory and clinical best practices for the application of cWGS. Founding member institutions of the Medical Genome Initiative incl
Tue Feb 26, 2019 16:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Cyclerion Therapeutics, Inc. (Cyclerion) has entered into an agreement for a private placement of up to $175 million. The offering includes commitments from existing Ironwood shareholders, new investors, and certain members of future Cyclerion management. Final proceeds from this offering are expected to support Cyclerion’s sGC stimulator portfolio for at least two years, including four clinica
Tue Feb 26, 2019 16:00
LUGANO, Suiza & BARCELONA, España--(BUSINESS WIRE)--Gain Therapeutics SA anuncia la concesión de una subvención por parte de las principales fundaciones de investigación de la enfermedad de Párkinson para promover el estudio de sus chaperonas farmacológicas no competitivas y patentadas en la enfermedad de Párkinson Gain Therapeutics SA, una compañía biotecnológica enfocada en descubrir y desarrollar terapias innovadoras para estabilizar las enzimas lisosomales involucradas en los errores innato
Tue Feb 26, 2019 15:40
CHICAGO--(BUSINESS WIRE)--SAMDI Tech Inc. now has well over 1 million compounds in its small molecule screening collection.
Tue Feb 26, 2019 15:05
WOBURN, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/arthritis?src=hash" target="_blank"gt;#arthritislt;/agt;--Romeg Therapeutics' GLOPERBA® is the first liquid formulation of colchicine approved by the FDA for the prophylaxis of gout flares in adults.
Tue Feb 26, 2019 15:00
HOUSTON & LONDON--(BUSINESS WIRE)--Cell Medica Awarded USD 8.7 Million CPRIT Grant to Accelerate CMD-502 Off-the-shelf CAR-NKT Cell Therapy into Clinical Development
Tue Feb 26, 2019 15:00
BOULDER, Colo.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24CLVS&src=ctag" target="_blank"gt;$CLVSlt;/agt;--Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, 2018, and provided an update on the Company’s clinical development programs and regulatory and commercial outlook for 2019. “We are pleased to have renewed U.S. revenue growth in the fourth quarter, and with our maintenance treatment indication approved in the EU, we...
Tue Feb 26, 2019 15:00
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation Announces Key Regulatory Updates for REVLIMID® in Lymphoma and Luspatercept in MDS and Beta-Thalassemia
Tue Feb 26, 2019 14:30
DUBLIN--(BUSINESS WIRE)--The "Amyloidosis Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering. "Amyloidosis Global Clinical Trials Review, H2, 2018" provides an overview of Amyloidosis clinical trials scenario. This report provides top line data relating to the clinical trials on Amyloidosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of
Tue Feb 26, 2019 14:25
NEUCHATEL, Suiza--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) anunció hoy las conclusiones de una serie de cuatro casos clínicos, recientemente publicados en el Canadian Journal of Anesthesiology, en los cuales los investigadores de la Universidad de Montreal detectaron que el uso combinado del monitoreo de la función cerebral con Masimo SedLine® y de oximetría regional O3® contribuyó a su comprensión y a la gestión de desaturaciones cerebrales durante cirugías cardíacas. Los doctores Etienne Coutur
Tue Feb 26, 2019 14:21
NEUCHÂTEL, Suisse--(BUSINESS WIRE)--Masimo (NASDAQ : MASI) a annoncé aujourd’hui les résultats d’une série de quatre cas cliniques, récemment publiés dans le Canadian Journal of Anesthesiology, dans lesquels les chercheurs de l’Université de Montréal ont découvert que l’utilisation combinée de la surveillance de la fonction cérébrale SedLine®et de l’oxymétrie régionale O3®de Masimo facilitait leur compréhension et leur prise en charge des désaturations cérébrales pendant la chirurgie cardiaque.
Tue Feb 26, 2019 14:17
NEUENBURG, Schweiz--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) hat heute die Befunde einer Reihe von vier klinischen Fällen bekannt gegeben, die unlängst im Canadian Journal of Anesthesiology veröffentlicht wurden. Dabei kamen Wissenschaftler der Universität Montreal zum Schluss, dass der kombinierte Einsatz der Masimo-Produkte SedLine® zur Überwachung der Gehirnfunktion und O3® für regionale Oxymetrie hilfreich ist, um zerebrale Entsättigungen während herzchirurgischen Eingriffen besser verstehen
Tue Feb 26, 2019 14:15
NEW YORK--(BUSINESS WIRE)--Ophthotech announced financial and operating results for the fourth quarter and full year ended December 31, 2018, and provided a business update.
Tue Feb 26, 2019 14:15
NEUCHÂTEL, Suíça--(BUSINESS WIRE)--A Masimo (NASDAQ: MASI) anunciou hoje as conclusões de uma série de quatro casos clínicos recém-publicados no periódico Canadian Journal of Anesthesiology, em que pesquisadores da Universidade de Montreal constataram que o uso do monitoramento de função cerebral SedLine® e da oximetria regional O3® da Masimo auxiliam no entendimento e no controle das dessaturações cerebrais durante a cirurgia cardíaca. Os Drs. Etienne Couture, Alain Deschamps e André Denault a
Tue Feb 26, 2019 14:13
LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--Asana BioSciences names Shashank Mahashabde and Pablo Jimenez to leadership team as ASN002 atopic dermatitis treatment advances in Phase 2b trial.
Tue Feb 26, 2019 14:00
NEW YORK & VIENNA--(BUSINESS WIRE)--HOOKIPA Pharma today announced that it has completed a $37.4 million (€33.2 million) series D financing.
Tue Feb 26, 2019 14:00
NEW YORK--(BUSINESS WIRE)--Rocket Pharmaceuticals Announces Publication of Comprehensive Review of Danon Disease Cases in the International Journal of Cardiology
Tue Feb 26, 2019 14:00
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced positive results from the Phase III POLO trial. Results from the trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) with LYNPARZA versus placebo. The safety and tolerability profile of LYNPARZA was consistent with previous trials. POLO is a randomized, double-blinded, placebo-
Tue Feb 26, 2019 13:55
DUBLIN--(BUSINESS WIRE)--The "Amnesia Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering. "Amnesia Global Clinical Trials Review, H2, 2018" provides an overview of Amnesia clinical trials scenario. This report provides top line data relating to the clinical trials on Amnesia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinica
Tue Feb 26, 2019 13:55
KENILWORTH, N.J.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24MRK&src=ctag" target="_blank"gt;$MRKlt;/agt; lt;a href="https://twitter.com/hashtag/MRK?src=hash" target="_blank"gt;#MRKlt;/agt;--LYNPARZA® Reduced Risk of Disease Progression or Death as First-Line Maintenance Treatment in Germline BRCA-Mutated Metastatic Pancreatic Cancer
Tue Feb 26, 2019 13:55
DUBLIN--(BUSINESS WIRE)--The "Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering. "Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy Global Clinical Trials Review, H2, 2018" provides an overview of Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy clinical trials scenario. This report provides top line data relating to the
Tue Feb 26, 2019 13:45
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced the submission of pivotal clinical data from the ARTISAN-SNM pivotal clinical study designed to gain marketing approval from the U.S. Food & Drug Administration (“FDA”) for the Axonics r-SNM® System1. Th
Tue Feb 26, 2019 13:00
LUGANO, Zwitserland & BARCELONA, Spanje--(BUSINESS WIRE)--Gain Therapeutics SA (een biotechnologisch bedrijf dat nieuwe therapeutica ontdekt en ontwikkelt om lysosomale enzymen die betrokken zijn bij aangeboren stofwisselingsfouten en ziekten van het centrale zenuwstelsel aan te pakken) kondigde vandaag aan dat het financiële steun heeft ontvangen van de Michael J. Fox Foundation for Parkinson’s Research (MJFF) en de Silverstein Foundation for Parkinson’s met GBA om zijn eigen niet-competitieve
Tue Feb 26, 2019 11:43
INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim and GNA Biosolutions announce that they have entered into a research collaboration focused on the development of a rapid African swine fever (ASF) diagnostic test. The test would be used in combination with GNA's portable molecular diagnostic platform, and is aimed at supporting the fight against the worldwide spread of this deadly disease. ASF is a devastating viral infection of swine causing severe clinical disease and high mortality.
Tue Feb 26, 2019 11:17
ATLANTA & ZURICH--(BUSINESS WIRE)--Lori Chmura, CEO of Dune Medical Devices, maker of the successful MarginProbe device, is scheduled to present at the 1st Sachs “Go For Israel” Life Sciences Conference on Tuesday, February 26th at 3:15 p.m. CET at the Hilton Zurich Airport, Zurich, Switzerland. Dune Medical Devices is a commercial-stage company revolutionizing tissue characterization technology in breast cancer surgery, diagnosis and targeted treatment with its proprietary Radio-Frequency Spec
Tue Feb 26, 2019 11:05
TQJ230 was discovered by Ionis and has been co-developed to date by Akcea and Ionis. Novartis is now responsible for worldwide development and commercialization of this asset. Millions The post Novartis to pursue transformational therapy to reduce risk of cardiovascular disease appeared first on Pharmaceutical Business review.
Tue Feb 26, 2019 11:14
THEMIS was conducted in over 19,000 patients with coronary artery disease (CAD) and type-2 diabetes (T2D) with no prior heart attack (myocardial infarction, MI) or stroke. Preliminary safety The post Brilinta’s phase 3 THEMIS trial met primary endpoint in patients with established coronary artery disease and type-2 diabetes appeared first on Pharmaceutical Business review.
Tue Feb 26, 2019 11:14
LUGANO, Svizzera e BARCELLONA, Spagna--(BUSINESS WIRE)--Gain Therapeutics SA (un’azienda biotecnologica che scopre e sviluppa terapie innovative mirate a enzimi lisosomiali coinvolti in errori congeniti del metabolismo e in malattie del sistema nervoso centrale) oggi ha annunciato di avere ricevuto un contributo finanziario dalla Michael J. Fox Foundation (MJFF) e dalla Silverstein Foundation per per la ricerca sul morbo sul GBA nel Parkinson, allo scopo di sviluppare i suoi chaperon molecolari
Tue Feb 26, 2019 09:30
LUGANO, Suisse, et BARCELONE, Espagne--(BUSINESS WIRE)--Gain Therapeutics SA annonce l'obtention d'une subvention de la part de grandes fondations de recherche pour faire progresser le développement de ses chaperons moléculaires non concurrentiels propriétaires dans la lutte contre la maladie de Parkinson Gain Therapeutics SA (une société de biotechnologie active dans la découverte et le développement de thérapies novatrices ciblant les enzymes lysosomales liées aux erreurs innées du métabolism
Tue Feb 26, 2019 09:30
LUGANO, Switzerland & BARCELONA, Spain--(BUSINESS WIRE)--Gain Therapeutics Announces Award of Grant Support from Leading Parkinson’s Research Foundations to Advance Its Proprietary Non Competitive Molecules.
Tue Feb 26, 2019 09:30
CAMBRIDGE, England--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/IBD?src=hash" target="_blank"gt;#IBDlt;/agt;--PredictImmune announce issuance of new patent in the US in support of commercialisation.
Tue Feb 26, 2019 09:30
LUGANO, Schweiz, und BARCELONA, Spanien--(BUSINESS WIRE)--Gain Therapeutics SA (ein Biotechnologieunternehmen, das sich auf die Erforschung und Entwicklung neuartiger Therapien konzentriert, die auf lysosomale Enzyme abzielen, welche an angeborenen Stoffwechselstörungen und Erkrankungen des Zentralnervensystems beteiligt sind) gab heute bekannt, dass es finanzielle Unterstützung von der Michael J. Fox Foundation for Parkinson’s Research (MJFF) und der Silverstein Foundation for Parkinson’s with
Tue Feb 26, 2019 09:30
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου